Literature DB >> 7989476

Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.

R L Rosenfield1, R B Barnes, D A Ehrmann.   

Abstract

Plasma 17-hydroxyprogesterone (17PROG) hyperresponsiveness to GnRH agonist (nafarelin) testing is typical of polycystic ovary syndrome and other functional ovarian hyperandrogenism (FOH) that does not meet customary criteria for the diagnosis of polycystic ovary syndrome. We have postulated that this results from abnormal regulation of androgen secretion. Whether this dysregulation is the result of a normal physiological response to ovarian hyperstimulation or escape from down-regulation of steroidogenesis is unknown. To distinguish between these possibilities, we have analyzed the ovarian steroid responses to nafarelin for the apparent efficiency of the steroidogenic steps and the apparent dose-response relationships between blood LH and steroid levels. We compared normal women (n = 18) with three groups of hyperandrogenic women (n = 15-19/group): patients with 17PROG hyperresponsiveness with or without elevated LH levels (type 1 and type 2 FOH, respectively) and patients with normal 17PROG responses to nafarelin (nafarelin negative). Subjects were pretreated with dexamethasone to suppress coincidental adrenal contributions to plasma steroid levels. The pattern of steroid secretion was similarly abnormal in both types of FOH, with the high LH group having generally more severe abnormalities in the levels of steroid intermediates. Baseline 17PROG and 17-hydroxypregnenolone and the ratio of 17PROG to androstenedione (AD) were increased (P < 0.05). In addition, the apparent slope of the 17PROG response to LH was significantly increased. Baseline levels of both AD and dehydroepiandrosterone and the AD response to nafarelin were increased, yet the ratio of peak minus baseline (delta) AD/delta 17PROG (another index of 17,20-lyase activity) was subnormal in FOH. The apparent slope of the testosterone (T) response to LH was significantly increased, and indexes of aromatase activity [estradiol (E2)/T and delta estradiol/delta T] were significantly decreased. Nafarelin stimulated plasma E2 in all groups to rise along an apparently similar LH-E2 dose-response slope. We interpret these results as indicating that FOH patients have generalized overactivity of thecal steroidogenesis, but nevertheless compensate so as to maintain a normal dose-response relationship between blood levels of LH and E2. FOH patients, whether they have LH excess or not, seen to form excessive 17PROG and incompletely dampen (down-regulate) thecal cell 17PROG, AD, and T secretion in response to LH stimulation. 17PROG hyperresponsiveness to nafarelin seems to be prominent both because it is formed in excess and because 17,20-lyase efficiency is rate limiting. The T elevation seems to arise mainly from overactive steroidogenesis, but also partly from an additional functional decrease in aromatase efficiency, which is secondary to negative feedback by the substrate-driven tendency toward estrogen excess.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989476     DOI: 10.1210/jcem.79.6.7989476

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  26 in total

1.  Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome.

Authors:  Marcus A Rosencrantz; Mickey S Coffler; Annette Haggan; Kimberly B Duke; Michael C Donohue; Rana F Shayya; H Irene Su; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2011-01-26       Impact factor: 5.958

2.  Potential diagnostic utility of intermittent administration of short-acting gonadotropin-releasing hormone agonist in gonadotropin deficiency.

Authors:  Carrie A Zimmer; David A Ehrmann; Robert L Rosenfield
Journal:  Fertil Steril       Date:  2010-05-31       Impact factor: 7.329

Review 3.  Neuroendocrine dysfunction in PCOS: a critique of recent reviews.

Authors:  Suhail A R Doi
Journal:  Clin Med Res       Date:  2008-09

4.  17-Hydroxyprogesterone responses to human chorionic gonadotropin are not associated with serum anti-Mullerian hormone levels among adolescent girls with polycystic ovary syndrome.

Authors:  Jingwen Hou; Heidi Cook-Andersen; H Irene Su; Rana Shayya; Kevin H Maas; Christine M Burt-Solorzano; Ajay Kumar; R Jeffrey Chang
Journal:  J Pediatr Endocrinol Metab       Date:  2016-07-01       Impact factor: 1.634

Review 5.  Androgen excess and metabolic disorders in women with PCOS: beyond the body mass index.

Authors:  R A Condorelli; A E Calogero; M Di Mauro; L M Mongioi'; R Cannarella; G Rosta; S La Vignera
Journal:  J Endocrinol Invest       Date:  2017-09-23       Impact factor: 4.256

6.  Endocrine antecedents of polycystic ovary syndrome in fetal and infant prenatally androgenized female rhesus monkeys.

Authors:  David H Abbott; Deborah K Barnett; Jon E Levine; Vasantha Padmanabhan; Daniel A Dumesic; Steve Jacoris; Alice F Tarantal
Journal:  Biol Reprod       Date:  2008-04-02       Impact factor: 4.285

7.  Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.

Authors:  Vanita R Aroda; Theodore P Ciaraldi; Paivi Burke; Sunder Mudaliar; Paul Clopton; Susan Phillips; R Jeffrey Chang; Robert R Henry
Journal:  J Clin Endocrinol Metab       Date:  2008-11-04       Impact factor: 5.958

8.  Increased androgen response to follicle-stimulating hormone administration in women with polycystic ovary syndrome.

Authors:  Deborah S Wachs; Mickey S Coffler; Pamela J Malcom; Shunichi Shimasaki; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2008-02-19       Impact factor: 5.958

Review 9.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

10.  Relationship between 17-hydroxyprogesterone responses to human chorionic gonadotropin and markers of ovarian follicle morphology in women with polycystic ovary syndrome.

Authors:  Kevin H Maas; Sandy S Chuan; Heidi Cook-Andersen; H Irene Su; A Duleba; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.